MedDataX Logo

Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

NCT ID: NCT03571997

Last Updated: 2022-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-15

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central \[CNS\], bone marrow \[MO\], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma

NCT01369784

Diffuse Large B-cell Lymphoma
COMPLETED

Study on Plasmablastic Lymphoma Patients

NCT06781359

Plasmablastic Lymphoma
RECRUITING

A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma

NCT00944567

Primary Mediastinal B-Cell Lymphoma
COMPLETED

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

NCT06024694

Primary Mediastinal Large B-cell Lymphoma (PMBCL)
ACTIVE_NOT_RECRUITING

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01197560

Diffuse Large B-cell Lymphoma
COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central \[CNS\], bone marrow \[MO\], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present. Analysis of the main clinical-biological variables as independent risk factors in adult patients (\> 15 years) diagnosed with ALL

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoblastic Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients \>15 years old diagnosed with ALL and treated with the PETHEMA protocols for ALL

Exclusion Criteria

None
Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

PETHEMA Foundation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Mútua de Terrassa

Terrassa, Barcelona, Spain

Site Status RECRUITING

Hospital Central de Asturias

Oviedo, Principality of Asturias, Spain

Site Status RECRUITING

Hospital General de Alicante

Alicante, , Spain

Site Status RECRUITING

H. de la Santa Creu I Sant Pau

Barcelona, , Spain

Site Status RECRUITING

H. Vall d'Hebron, Barcelona

Barcelona, , Spain

Site Status RECRUITING

H.Universitari Germans Trias I Pujol de Badalona

Barcelona, , Spain

Site Status RECRUITING

Hospital Clínic de Barcelona

Barcelona, , Spain

Site Status RECRUITING

Hospital de Basurto

Basurto, , Spain

Site Status RECRUITING

ICO-Duran i Reynals

Bellvitge, , Spain

Site Status RECRUITING

Hospital Donostia

Donostia / San Sebastian, , Spain

Site Status RECRUITING

H. Univ. de Girona Dr. Josep Trueta (ICO)

Girona, , Spain

Site Status RECRUITING

Hospital Arnau de Vilanova (Lleida)

Lleida, , Spain

Site Status RECRUITING

Hospital Lucus Augusti

Lugo, , Spain

Site Status RECRUITING

H. Gregorio Marañón

Madrid, , Spain

Site Status RECRUITING

Hospital San Pedro de Alcántara.

Málaga, , Spain

Site Status RECRUITING

Hospital General Universitario Morales Messeguer

Murcia, , Spain

Site Status RECRUITING

Hospital Son Espases

Palma de Mallorca, , Spain

Site Status RECRUITING

Hospital Son Llatzer

Palma de Mallorca, , Spain

Site Status RECRUITING

Complejo Hospitalario de Navarra

Pamplona, , Spain

Site Status RECRUITING

Parc Taulí

Sabadell, , Spain

Site Status RECRUITING

H. Univ. de Salamanca

Salamanca, , Spain

Site Status RECRUITING

C. H. U. de Santiago

Santiago de Compostela, , Spain

Site Status RECRUITING

Complejo Hosp. Regional Virgen del Rocío

Seville, , Spain

Site Status RECRUITING

Hospital del Valme

Seville, , Spain

Site Status RECRUITING

H. Joan XXIII

Tarragona, , Spain

Site Status RECRUITING

Hoapital La Fe

Valencia, , Spain

Site Status RECRUITING

Hospital Arnau de Vilanova (Valencia)

Valencia, , Spain

Site Status RECRUITING

Hospital Universitari Clínic València

Valencia, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Miguel Sagüés Serrano, Dr

Role: CONTACT

[email protected]
972 225 158

Josep Mª Ribera, Dr

Role: CONTACT

[email protected]|
93 4978987 (ext. 3939)

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ferran Vall-Llovera

Role: primary

Teresa Bernal

Role: primary

Cristina Gil

Role: primary

Irene García Cadenas

Role: primary

Pere Barba

Role: primary

Josep Maria Ribera

Role: primary

Jordi Esteve

Role: primary

Cristina Barrenetxea Lekue

Role: primary

Santiago Mercadal

Role: primary

Teresa Artola

Role: primary

Rosa Coll

Role: primary

Antoni Garcia-Guiñon

Role: primary

María José Sánchez Sánchez

Role: primary

Silvia Monsalvo

Role: primary

Bergua Juan, Dr

Role: primary

Maria Luz Amigo

Role: primary

Andrés Novo

Role: primary

Antònia Cladera

Role: primary

Maria Carmen Mateos Rodríguez

Role: primary

Sonia Piernas

Role: primary

Jesús María Hernández Rivas

Role: primary

Natalia Alonso, Dr

Role: primary

José González Campos, Dr

Role: primary

Maria Ángeles Domínguez

Role: primary

Marta Cervera

Role: primary

Pau Montesinos

Role: primary

Aurelio López

Role: primary

Mar Tormo

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FPLLA-PETHEMA-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496 ACTIVE_NOT_RECRUITING PHASE1
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
NCT06733987 RECRUITING
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL
NCT03971318 UNKNOWN
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
NCT01110733 COMPLETED
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
NCT05162170 COMPLETED
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas
NCT02788916 COMPLETED
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
NCT00425555 COMPLETED PHASE2
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT03340766 COMPLETED PHASE1
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
NCT05700149 RECRUITING
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry
NCT04587388 RECRUITING
Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
NCT06781450 RECRUITING
PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors
NCT05078840 RECRUITING
Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia
NCT02618109 TERMINATED PHASE4
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT03104478 COMPLETED
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
NCT01556035 COMPLETED PHASE2
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
NCT01478269 COMPLETED
Transplantation After Complete Response In Patients With T-cell Lymphoma
NCT05444712 RECRUITING NA
TREatment of degeNerative and Neoplastic Diseases With Rituximab
NCT01277172 UNKNOWN PHASE2/PHASE3
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 RECRUITING PHASE2
R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients
NCT03364439 COMPLETED PHASE2
Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
NCT06422247 COMPLETED
Lenalidomide Maintenance Post-debulking in Advanced CTCL
NCT01098656 TERMINATED PHASE3
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05182957 UNKNOWN PHASE2
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
NCT06089941 ACTIVE_NOT_RECRUITING
Indolent Non Follicular Lymphomas Prognostic Project
NCT02904577 COMPLETED